Sat, Nov 22, 2014, 4:43 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

  • lws2000 lws2000 Feb 12, 2013 11:01 AM Flag

    Geron and Celgene

    Both have unique Oncology products. Geron's innovations and successes with telemeres fits well with Celgene's established products and their deep pockets. I believe this is a likely combination, since Celgene is looking for diversification.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Telermeres sound very exciting. Celgene sounds like the best "deep pockets" to back this research.

    • Imetelstat seems to have much potential.

      "Imetelstat (GRN163L) is a potent and specific inhibitor of telomerase currently in clinical development as a potential therapeutic agent for the treatment of solid tumor and hematological malignancies. This first-in-class compound is a specially designed and modified oligonucleotide, which targets and binds directly to the active site of telomerase with high affinity. The proprietary oligonucleotide chemistry and lipid modification improves binding affinity and stability, and enables good cellular and tissue penetration, even at lower concentrations."

    • Celgene maintains continuing interst in Ongology & Telemeres
      Now that the potential for "telemere therapy" has been established, one of the major drug companies will take a big part of the company, perhaps all of it. Geron means "pipeline", and for Celgene this means new products in "medicine of the future".

      I believe that telemeres are dlose to the "holy grail" of modern medicine and cancer research.. Geron is the first with a breakthrough, and may be the most rewarded by the medical community and the investment community. I am surprised that the stock is still so low.

    • Celgene has a market cap of 42 billion. It's interesting that Geron's Imetelstat in Phase II clinical trial is for Multiple myeloma, While presently Celgene has THALOMID used in combination with dexamethasone for patients with newly diagnosed multiple myeloma.

      Perhaps a combo of Thalomid, Imetelstat, and Dexamethasone might be worth look at by Celgene.

 
GERN
3.70+0.45(+13.85%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exa Corporation
NasdaqGMFri, Nov 21, 2014 3:59 PM EST
Hexcel Corp.
NYSEFri, Nov 21, 2014 4:02 PM EST